SBC Medical Group
SBC Medical Group's revenue fell 15.5% to $174 million in fiscal 2025. Its operating margin was 38.9%, up from 34.2% a year earlier. Free cash flow was $23 million, up 29.1%. It paid out $5 million in dividends and buybacks, 21% of free cash flow. The diluted share count rose 6.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2023 to 2025, earnings per share grew 9.1% a year and net income 13.8% a year, as new shares raised the share count by 9% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 103 | 125 | 164 |
| Debt incl. finance leases | 15 | 7 | 43 |
| Net debt (negative means net cash) | −88 | −118 | −121 |
| Net debt to EBITDA | −1.1x | −1.6x | −1.7x |
| Debt to equity | 0.1x | 0.0x | 0.2x |
| Interest coverage | 1,560.1x | 2,484.2x | 455.3x |
| Current ratio | 1.8x | 3.0x | 3.8x |
| Quick ratio | 1.8x | 3.0x | 3.7x |
Cash flow
Projections
Project SBC Medical Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought SBC Medical Group shares on the open market, and 1 insider sold $20.1 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Yoshiyuki AikawaChairman and CEO, Director, 10% owner | Sold | 465,000 | $3.02 | $1.4 million | Form 4 |
| Apr 21, 2026 | Yoshiyuki AikawaChairman and CEO, Director, 10% owner | Sold | 3,100,000 | $3.02 | $9.4 million | Form 4 |
| Mar 6, 2026 | Yoshiyuki AikawaChairman and CEO, Director, 10% owner | Sold | 4,422,900 | $2.12 | $9.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | 4 of 9 |
| Rule of 40 | 14.9% | −2.1% |
| Altman Z'' | 10.02 | 8.55 |
| Accruals ratio | 9.9% | 8.1% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Pass | Pass |
| Cash from operations is positive | Pass | Pass |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Fail | Fail |
| Debt fell relative to assets | — | Fail |
| Current ratio rose | Pass | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Fail |
| Revenue rose relative to assets | — | Fail |
| F-score | — | 4 of 9 |
Compare
Put SBC Medical Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SBC Medical Group | FY25 | −15.5% | 38.9% | 13.4% | 38.4% | −1.7x | 4 | |
| biote | FY25 | −2.5% | 18.5% | 15.7% | — | 2.0x | 5 | Compare |
| LifeMD | FY25 | 25.3% | −4.0% | 3.3% | — | — | — | Compare |
| Strata Critical Medical | FY25 | 34.3% | −11.3% | −29.7% | −11.3% | — | 4 | Compare |
| AirSculpt Technologies | FY25 | −15.8% | −7.6% | 0.5% | −6.6% | 39.0x | 3 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 194 | 205 | 174 |
| Revenue growth | — | 6.1% | −15.5% |
| Gross profit | 137 | 156 | 127 |
| Research and development | — | — | — |
| Operating income | 71 | 70 | 68 |
| Net income | 39 | 47 | 51 |
| Diluted EPS (US$) | 0.42 | 0.48 | 0.50 |
| Diluted shares (millions) | 94 | 97 | 103 |
| Cash flow | |||
| Cash from operations | 51 | 21 | 25 |
| Capital expenditure | 8 | 3 | 1 |
| Free cash flow | 42 | 18 | 23 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 5 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | — | 13 | 0 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 103 | 125 | 164 |
| Debt incl. finance leases | 15 | 7 | 43 |
| Total assets | 259 | 266 | 380 |
| Total liabilities | 115 | 71 | 117 |
| Shareholders' equity | 142 | 195 | 248 |
| Margins and ratios | |||
| Gross margin | 70.9% | 76.0% | 73.3% |
| Operating margin | 36.5% | 34.2% | 38.9% |
| Net margin | 20.3% | 22.7% | 29.4% |
| Free cash flow margin | 21.8% | 8.8% | 13.4% |
| Rule of 40 (growth + FCF margin) | — | 14.9% | −2.1% |
| Return on capital | — | 67.4% | 38.4% |
| Return on equity | — | 27.6% | 23.0% |
| Return on assets | — | 17.8% | 15.8% |
| Net debt to EBITDA | −1.1x | −1.6x | −1.7x |